Brief: Vicore Announces Positive Final Results From Phase 2a AIR Trial

Vicore Pharma Holding AB

20/05/2024 07:17

May 20 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * ANNOUNCES POSITIVE FINAL RESULTS FROM THE PHASE 2A AIR
TRIAL
DEMONSTRATING BULOXIBUTID IMPROVES LUNG FUNCTION OVER 36 WEEKS
IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    * BULOXIBUTID IMPROVED LUNG FUNCTION-MEASURED BY FVC-BY OVER
200
ML FROM BASELINE AT 36 WEEKS OF TREATMENT
    * THERAPY WAS SAFE AND WELL TOLERATED WITH NO
TREATMENT-RELATED
SERIOUS ADVERSE EVENTS
    * PLANS TO PROGRESS BULOXIBUTID TO PHASE 2B DEVELOPMENT IN
FIRST
HALF OF THIS YEAR

Source text for Eikon:  ID:nMFN3DJJSP 
Further company coverage:  VICOR.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))